Establishing patient safety monitoring in the benefit-risk paradigm for off-label and emergency use of medications for COVID-19: A pharmacovigilance perspective

• Marina A. Malikova,
• Marina A. Malikova,
• Gianluca Trifirò,
• Giorgio Racagni,
• Dennis Van Liew,
• Peggy Webster,
• Tejal S. Brahmbhatt,
• Tejal S. Brahmbhatt

Affiliations

Marina A. Malikova

Department of Surgery, School of Medicine, Boston University, Boston, MA, United States

Marina A. Malikova

Boston Medical Center, Boston, MA, United States

Gianluca Trifirò

Department of Diagnostics and Public Health, University of Verona, Verona, Italy

Giorgio Racagni

Department of Pharmacological and Biomolecular Sciences, Faculty of Pharmacy, University of Milan, Milan, Italy

Dennis Van Liew

Red Nucleus, Waltham, MA, United States

Peggy Webster

Glaxo SmithKline, Cambridge, MA, United States

Tejal S. Brahmbhatt

Department of Surgery, School of Medicine, Boston University, Boston, MA, United States

Tejal S. Brahmbhatt

Boston Medical Center, Boston, MA, United States